Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
WITH MILLIONS OF AMERICANS SUFFERING FROM COLD AND FLU SYMPTOMS EACH YEAR IT’S A GOOD IDEA TO KEEP YOUR HOUSE STOCKED WITH THE RIGHT DEFENSES. NATIONALLY RECOGNIZED MEDICAL EXPERT AND RN, LINDA CIAMPA, HAS SOME OF THE BEST SYMPTOM FIGHTING TOOLS TO HELP GET YOU AND YOUR FAMILY THROUGH THIS COLD AND FLU SEASON.
http://www.bestbuyuniforms.com Best Buy Uniforms offers chef, work, career, security, medical, formal uniforms and accessories at wholesale prices to corporate America.
Boehringer Ingelheim announced today a new partnership with Minor League Baseball® (MiLB™) to further raise awareness of the rare lung disease idiopathic pulmonary fibrosis (IPF) through its Breathless™ campaign. Now the “Official IPF Awareness Partner of Minor League Baseball,” Boehringer Ingelheim will work with the league to educate its fan base about symptoms of IPF – and the importance of an early diagnosis and treatment – through in-stadium events as well as appearances by New York Yankees legend and musician Bernie Williams, whose father passed away from the disease in 2001.
To view the multimedia release go to:
https://www.multivu.com/players/English/8289951-boehringer-ingelheim-milb-partnership-for-ipf-awareness/
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
Weill Cornell Medical College today opened the Belfer Research Building, a state-of-the-art facility that ushers in a new era at the institution for cutting-edge, translational science. The 18-story, $650 million building, made possible through the generosity of numerous donors, nearly doubles Weill Cornell’s existing research space and empowers scientists to rapidly translate groundbreaking discoveries into the most advanced patient care.
To view Multimedia News Release, go to http://www.multivu.com/mnr/65415-weill-cornell-medical-college-belfer-cancer-research-building-opening
Global health service company Cigna Corporation (NYSE: CI) today unveiled a new initiative championing its whole person approach to health and well-being. The company is bringing together three cultural icons, Queen Latifah, Nick Jonas and Ted Danson, to encourage everyone to schedule their annual check-up and talk openly and honestly with their health care providers about how they are feeling, physically and emotionally.
Filmed in Los Angeles, the campaign takes a public service message approach and features the three influencers taking unique steps to find balance in their hectic personal and professional lives. Using light humor, they each address the impact that widespread and relatable feelings, such as stress and loneliness, can have on overall health and well-being.
To view the multimedia release go to:
https://www.multivu.com/players/English/8454551-cigna-latifah-jonas-danson-go-know-take-control/
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA) for the BD Veritor™ System for rapid detection of Flu A+B. This is the first rapid influenza test system that incorporates a digital read out of results to receive CLIA waiver.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53615-bd-veritor-system-influenza-test-receives-510k-clearance-fda-clia-waiver
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and expert services at this year's American Society of Health-System Pharmacists (ASHP) 2017 Midyear Meeting being held in Orlando from Dec. 3-7.
With direct medical costs associated with medication errors reaching $21 billion worldwide, innovative strategies must be developed to address the grand health challenges associated with medication management. BD has been evolving its focus to re-invent medication management with integration of the company’s technologies, analytics and expert services that aim to close the communication gaps across disparate solutions. The BD HealthSight platform connects systems and processes to help hospitals and health systems drive a safer, more efficient medication management process.
To view the multimedia release go to:
https://www.multivu.com/players/English/8198551-bd-healthsight-platform-ashp-2017/
With 830 women dying every day from preventable causes related to pregnancy and childbirth, and over 16,000 children under age five dying daily, Bayer and the White Ribbon Alliance today released critical policy recommendations and launched community programs to support the reduction and prevention of maternal, newborn and child mortality in two developing countries.1,2
Established through a three-year $1.3 million commitment from Bayer, these programs will expand work conducted by White Ribbon Alliance in Bangladesh and Zimbabwe to support the United Nations Secretary General’s Every Woman Every Child movement.
This announcement comes at the one-year anniversary of the Bayer/White Ribbon Alliance commitment in support of the Every Woman Every Child movement and will contribute to the success of the Sustainable Development Goals.
To view the multimedia release go to:
http://www.multivu.com/players/English/77126510-bayer-white-ribbon-alliance-self-care/
Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology.
The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks.
To view the multimedia release go to:
https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
